Clinical Trial Update: Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of NBI-1117568 in adults with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NBI-1117568

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED